Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Managing asfotase alfa (Strensiq) injections with your doctor depends on several factors, and the important details are below. This enzyme replacement therapy for hypophosphatasia is given as a subcutaneous injection several times per week, with the dose calculated by body weight and re-adjusted by your clinician as your weight changes over time. Safe use includes correct refrigerated storage, rotating injection sites, avoiding skin that is red, bruised, or hardened, and tracking reactions such as pain, swelling, or fat loss at the site. Your doctor should also arrange ongoing monitoring, including eye exams and kidney imaging for calcium deposits, plus prompt reporting of allergic symptoms, new bone pain, or missed doses.
If you are noticing new symptoms, side effects, or changes you cannot explain, a free, instant, online symptom check can help you organize what you are experiencing and understand which concerns deserve urgent attention, so your next conversation with your care team is faster, clearer, and more productive.
Last reviewed for medical accuracy: 08/18/2026
Asfotase alfa (brand name Strensiq) is an enzyme replacement therapy prescribed for hypophosphatasia, a rare inherited disorder affecting bone development. Regular injections help build stronger bones, improve muscle strength and enhance overall quality of life. Working closely with your healthcare team ensures you get the most benefit with the fewest complications.
Before starting therapy, your doctor will review medical history, perform physical exams and order baseline labs. Keep an up-to-date list of medications, supplements and allergies to share at every visit.
Picking the right injection spot and rotating locations helps reduce discomfort, bruising and the risk of tissue changes under the skin. Strensiq injection sites commonly include:
Safe rotation prevents repeated trauma to the same area. For example, if you inject in the right thigh today, try the left thigh or abdomen on your next dose. Keep a simple chart or mobile app log to track sites and dates.
Proper preparation ensures accurate dosing and lowers infection risk:
Storage
Gather supplies
Reconstitution (if needed)
Hand hygiene
Clean the site
Draw up the dose
Inject
Withdraw and apply pressure
Dispose safely
Mild side effects are common and often improve with time. Discuss any ongoing or severe symptoms with your doctor.
Management tips:
Management tips:
If you notice these, seek immediate medical attention or call emergency services. Always carry a list of your medications and your treating physician’s contact information.
Regular communication helps tailor treatment, monitor progress and catch issues early.
Schedule follow-up visits as recommended—often every 2–4 weeks at first, then every 3–6 months once stable.
Keeping a consistent record empowers both you and your doctor:
You might also consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you decide when to seek care or adjust your treatment plan.
Call emergency services or go to the nearest emergency department if you experience:
For any other concerns, contact your physician’s office promptly.
Asfotase alfa (Strensiq) injections can transform quality of life for people with hypophosphatasia when managed carefully. Partnering with your doctor on injection sites, monitoring for Strensiq injection side effects and keeping thorough records will help you stay on track.
Always speak to a doctor about any new, worsening or life-threatening symptoms. If you’re ever unsure whether a symptom warrants medical attention, use the free, online symptom check, using the doctor approved Ubie Symptom Checker or contact your healthcare provider right away. Your active involvement and timely communication are vital for safe, effective treatment.
(References)
* Orimo H. Pathophysiology of hypophosphatasia and the potential role of asfotase alfa. Ther Clin Risk Manag. 2016;12:777-86. doi: 10.2147/TCRM.S87956. Epub 2016 May 17. PMID: 27274262; PMCID: PMC4876073.
* Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, Taylor J, Phillips D, McGinn M, McAlister WH. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019 Feb;7(2):93-105. doi: 10.1016/S2213-8587(18)30307-3. Epub 2018 Dec 14. PMID: 30558909.
* Kishnani PS, Rockman-Greenberg C, Rauch F, Bhatti MT, Moseley S, Denker AE, Watsky E, Whyte MP. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019 Apr;121:149-162. doi: 10.1016/j.bone.2018.12.011. Epub 2018 Dec 18. PMID: 30576866.
* Simon S, Resch H. Treatment of hypophosphatasia. Wien Med Wochenschr. 2020 Apr;170(5-6):112-115. doi: 10.1007/s10354-020-00736-3. Epub 2020 Feb 18. PMID: 32072352.
* Schroth RJ, Long C, Lee VHK, Alai-Towfigh H, Rockman-Greenberg C. Dental outcomes for children receiving asfotase alfa for hypophosphatasia. Bone. 2021 Nov;152:116089. doi: 10.1016/j.bone.2021.116089. Epub 2021 Jun 25. PMID: 34175501.
* Alsarraf F, Ali DS, Almonaei K, Al-Alwani H, Khan AA, Brandi ML. Hypophosphatasia: presentation and response to asfotase alfa. Osteoporos Int. 2024 Apr;35(4):717-725. doi: 10.1007/s00198-023-06943-z. Epub 2023 Nov 23. PMID: 37993691.
* Dahir KM, Shannon A, Dunn D, Voegtli W, Dong Q, Hasan J, Pradhan R, Pelto R, Pan WJ. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024 Sep 26;39(10):1412-1423. doi: 10.1093/jbmr/zjae128. PMID: 39135540; PMCID: PMC11425692.
* Padidela R, Bishop N, Arundel P, Fang S, Zygouras A, Mughal MZ, Shaw N, Saraff V. Mobility and Quality of Life in Children with Paediatric-Onset Hypophosphatasia Treated with Asfotase Alfa: Results from UK Managed Access Agreement. Adv Ther. 2025 Jul;42(7):3528-3546. doi: 10.1007/s12325-025-03225-4. Epub 2025 May 29. PMID: 40439960; PMCID: PMC12182503.
* Narisawa S, Amadeu de Oliveira F, Tokuhara CK, Lira Dos Santos EJ, Fonfria E, Batson J, Cheng Z, Houston A, Foster BL, Millán JL. ENPP1 inhibition as a therapeutic approach for later-onset hypophosphatasia. J Bone Miner Res. 2026 Mar 2;41(3):310-323. doi: 10.1093/jbmr/zjaf136. PMID: 41051346; PMCID: PMC13017400.
* Carrillo MA, Tomer S, Wang L, Cook E, Wennerberg W, Tien N, Ng H, Alagarsamy J, Rezek V, Martin H, Narisawa S, Millan JL, Crine P, Yan M, Lee S, Kim NJ, Rodriguez R, Bishop P, Sanchez R, Orpilla J, Le Verche V, Xu S, Chen ISY, Kitchen S, Breton L, Bartlett JS, Do MH, Zhen A. Lentivirus-based HPSC therapy provides effective and long-term treatment in hypophosphatasia mouse model. Mol Ther. 2026 Jul 1;34(7):4200-4211. doi: 10.1016/j.ymthe.2026.03.008. Epub 2026 Mar 10. PMID: 41814653; PMCID: PMC13330071.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.